SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending due to the release of FDA briefing documents for its melanoma candidate, RP1, which highlighted recurring concerns regarding trial design and efficacy data. Investors are bracing for volatility as the community remains sharply divided between those speculating on a short squeeze following a positive advisory committee outcome and those anticipating a potential third rejection and further dilution.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing a sharp sell-off as investors react to management's warnings regarding supply chain constraints and margin pressure stemming from rising memory costs. The community is actively debating whether this decline represents a buying opportunity for a long-term core holding or a fundamental breakdown that signals a broader correction ahead.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing significant downward pressure as investors react to weak forward bookings guidance and management's decision to withdraw annual financial outlooks. The community is sharply divided, with some traders framing the selloff as an overreaction and a long-term accumulation opportunity, while others point to mounting concerns over platform monetization, regulatory scrutiny, and decelerating user growth.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors focus on upcoming quarterly earnings, with strong community sentiment surrounding store growth and potential relisting news. Despite concerns over profit margins and competition, many remain optimistic about the company's long-term expansion and share buyback initiatives.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is facing significant volatility as shares slide following the pricing of a $375 million convertible notes offering, fueling intense community debate over potential dilution versus the strategic necessity of capital to secure future AI data center anchor tenants. While bears are highlighting the recent executive turnover and lack of immediate deals, bulls are pointing to heavy institutional accumulation, strong technical support, and the company's significant infrastructure permits as signals that the stock is oversold ahead of a major catalyst.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as retail sentiment turns increasingly bullish following recent European regulatory approval for the oral Wegovy pill and reports of robust early adoption in the UK. The community is actively debating the stock's valuation gap relative to Eli Lilly, with many investors pointing to Novo's expanding oral pipeline and script growth as catalysts for a potential breakout above key technical resistance levels.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is facing significant volatility ahead of its earnings report, with investor sentiment deeply divided over the impact of the pending Clarity Act and broader crypto market health. The community remains fixated on whether the company's subscription growth can offset trading revenue declines, while bulls monitor key technical support levels and potential legislative catalysts.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility and community frustration as investors debate the company's valuation, recent CEO leadership transition, and the competitive threat from other developers in the Duchenne muscular dystrophy space. While long-term bulls point to a robust siRNA pipeline and commercial revenue as signs of an undervalued asset, bears remain focused on the stock's persistent downward trend and uncertainty surrounding future growth catalysts.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is trending following a combination of robust script growth and significant institutional accumulation, with the community closely tracking its progress toward H2 2026 profitability. Investors are heavily debating the stock's potential for acquisition by Big Pharma, emphasizing its strong patent position and the continued scaling of Voquezna as a potential standard-of-care treatment in the gastroenterology space.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is facing significant selling pressure despite reporting strong quarterly revenue growth and beating earnings expectations, as investors express concerns regarding future user growth and the impact of AI search traffic. The community is sharply divided, with bulls viewing the pullback as a buying opportunity based on strong fundamentals, while bears argue the platform faces long-term risks from user attrition and perceived moderation issues.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVO Stock Slumps After Late-Stage Trial Fails Primary Goal – Retail Says ‘Current Revenue Drivers’ Still Intact

Novo Nordisk shares declined following the announcement that its Phase 3 ZEUS trial of the investigational drug ziltivekimab failed to meet its primary objective of reducing major adverse cardiovascular events. Despite this, the company confirmed that the trial results will not impact its 2026 adjusted operating profit outlook and that it will continue with other ongoing studies of the medication.

Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.

Key PointsBoth companies are giants in diabetes and obesity treatments...

Equity

Novo’s Phase 3 trial showed that investigational drug Ziltivekimab did not reduce major adverse cardiovascular events compared with the placebo


HIMS Stock Eyes 4-Week Losing Streak: Legal Woes Fuel ‘Very High’ Uncertainty As Analyst Sticks To ‘No Moat’ Call 

Morningstar maintained a ‘No Moat’ view, citing low telehealth barriers and offerings rivals can replicate “with relative ease.”

 VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t 

Viking expects oral VK2735 Phase 3 studies to begin in Q4 and believes the pill could become the first oral dual GLP-1 agonist to reach the market.

How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?

Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.

Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap...

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Key PointsAmgen wants a slice of the weight loss drug market...

Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing

Novo Nordisk (NVO) reached $50.96 at the closing of the latest trading day, reflecting a +2.6% change compared to its last close.

Where Will Novo Nordisk Stock Be in 3 Years?

Key PointsNovo Nordisk remains a step behind Eli Lilly in the weight loss drug market...

Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?

Key PointsEli Lilly's ads don't account for a new, higher dose of Novo Nordisk's Wegovy...

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

The stock faced sharp selling pressure following disappointing results from the ZEUS cardiovascular trial.

Traders are closely watching for the upcoming earnings report to see if growth guidance holds steady.

Market attention remains fixed on record sales and expansion for the oral Wegovy franchise despite pipeline noise.

Many investors view the recent price drop as a massive overreaction and are aggressively adding to their positions.

Feed

News

Sentiment

Earnings

Fundamentals

Info

NVONovo Nordisk A/S

Fundamentals

Connect Stocktwits to ChatGPT

Latest NVO News